InnovaRx Innova Health Strategies

F15.129

Other stimulant abuse with intoxication, unspecified

Billable FY2026 2025-10-01 → 2026-09-30
This is the unspecified option. 3 more specific codes sit alongside it. Worth checking whether the documentation supports one of them.
Exclusions 4 never code together
F15code
Excludes2
  • cocaine-related disorders (F14.-)F14.-
F15.1code
Excludes1
  • other stimulant dependence (F15.2-)F15.2-
  • other stimulant use, unspecified (F15.9-)F15.9-
F01-F99chapter
Excludes2
  • symptoms, signs and abnormal clinical laboratory findings, not elsewhere classified (R00-R99)R00-R99

Excludes1 — never code together. The excluded condition and this one are mutually exclusive.

Excludes2 — not included here, but the patient may have both. Code both when documented.

Instructional notes 4
Inclusion terms
  • Amphetamine or other stimulant use disorder, mild, with amphetamine or other stimulant intoxication, without perceptual disturbances
F15code
Includes
  • amphetamine-related disorders
  • caffeine
F01-F99chapter
Includes
  • disorders of psychological development
Index entries leading here 3
  • Abuse
    • amphetamine (or related substance) — see also Abuse, drug, stimulant NEC
    • drug NEC (non-dependent) F19.10
  • Disorder (of) — see also Disease
    • amphetamine (or other stimulant) use
      • mild
        • with
          • amphetamine, cocaine, or other stimulant intoxication
            • without perceptual disturbances F15.129
  • Intoxication
    • amphetamine (without dependence) — see also Abuse, drug, stimulant, with intoxication
Alongside this code 3 same parent — F15.12
Additional references
AHA Coding Clinic® Licence required

Official coding advice for this code. Published by the American Hospital Association. Not included in this installation.

Risk adjustment

CMS22HCC55 CMS28HCC137 ESRD21HCC55 ESRD24HCC55

Presence is a property of the code. Untick a model to hide it everywhere.

This code

Billable
yes
Code set
FY2026
Parent
F15.12
Block
F10-F19
Siblings
3

Present FY2024–FY2027.